Scarica l'app Stockscreener
16.61
2.69%
-0.46
Dopo l'orario di chiusura:
16.61
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACAD Giù?
Forum
Previsione
Precedente Chiudi:
$17.07
Aprire:
$16.71
Volume 24 ore:
1.69M
Relative Volume:
0.76
Capitalizzazione di mercato:
$2.79B
Reddito:
$890.53M
Utile/perdita netta:
$30.57M
Rapporto P/E:
92.28
EPS:
0.18
Flusso di cassa netto:
$80.53M
1 W Prestazione:
-3.60%
1M Prestazione:
-15.26%
6M Prestazione:
+8.00%
1 anno Prestazione:
-10.17%
Intervallo 1D:
$16.28
$16.88
Intervallo di 1 settimana:
$16.28
$17.39
Portata 52W:
$14.15
$20.68
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Confronta ACAD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
16.61 | 2.79B | 890.53M | 30.57M | 80.53M | 0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
ACADIA Pharmaceuticals Earns Relative Strength Rating Upgrade - Investor's Business Daily
Why Is Acadia (ACAD) Down 11.1% Since Last Earnings Report? - Yahoo Finance
Soleno breaks through with FDA nod for Prader-Willi syndrome treatment Vykat XR - Fierce Pharma
Soleno jumps as analysts say US nod for rare disease drug transforms treatment options - Marketscreener.com
SLNO Stock Rallies on FDA Approval of Prader-Willi Syndrome Drug - Yahoo Finance
Acadia Pharmaceuticals principal accounting officer sells $18k in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals CFO sells $54,065 in stock By Investing.com - Investing.com Canada
Acadia Pharmaceuticals principal accounting officer sells $18k in stock - Investing.com India
Acadia Pharmaceuticals CFO sells $54,065 in stock - Investing.com
Is ACADIA Pharmaceuticals Inc. (ACAD) a Promising Biotech Stock According to Wall Street Analysts - Insider Monkey
Psychosis in Parkinson's and Alzheimer's Disease Market: - openPR
Parkinson's Disease Psychosis Treatment Market Size in 7MM - openPR
Acadia Pharmaceuticals Initiates Phase 2 Clinical Trial of ACP-204 for the Treatment of Alzheimer’s Disease Psychosis - Business Wire
Acadia Pharmaceuticals Announces DAYBUE™ (trofinetide) is Now Available for the Treatment of Rett Syndrome - Business Wire
Is ACADIA Pharmaceuticals Inc. (ACAD) the Best Nasdaq Stock Under $20 to Buy Now? - Insider Monkey
ACADIA Pharmaceuticals Earns RS Rating Upgrade - Investor's Business Daily
Former San Diego Pharma VP pleads guilty to securities fraud for insider trading - MSN
Ryan Reynolds Announces More to Parkinson’s® Campaign - Business Wire
Acadia Pharmaceuticals issues new employee stock awards By Investing.com - Investing.com Australia
Acadia Pharmaceuticals issues new employee stock awards - Investing.com India
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Acadia Expands Neuroscience Team with Strategic Stock Grants to 13 Key Hires - Stock Titan
Acadia Sets Stage for Strategic Updates at 3 Major CNS ConferencesKey Dates for Investors - StockTitan
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress By Investing.com - Investing.com South Africa
ACADIA Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com India
Proficio Capital Partners LLC Invests $272,000 in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) - Defense World
Parkinson's Disease Therapeutics Market is expected to reach - openPR
ACADIA Pharmaceuticals Q4 Earnings: EPS Soars to $0.86, Beating Estimates, While Revenue Misses at $259.6 Million - GuruFocus.com
Calif. Pharma Exec Pleads Guilty To Insider Trading - Law360
SEC Sues Former Acadia Pharmaceuticals VP Over Insider Trading - Bloomberg Law News
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Acadia Pharmaceuticals (ACAD) Investors with Losses to Contact Its Attorneys, Firm Investigating ACAD for Possible Securities Law Violations - ACCESS Newswire
Former Vice President of San Diego-Based Acadia Pharmaceutical Company Admits to Insider Trading - Sierra Sun Times
ACADIA Pharmaceuticals (NASDAQ:ACAD) Earns Equal Weight Rating from Morgan Stanley - Defense World
Ex-San Diego pharma VP pleads guilty to securities fraud for insider trading - ABC 10 News San Diego KGTV
Former Acadia Pharmaceuticals VP Pleads Guilty to Insider Trading in San Diego Federal Court - Hoodline
Former Executive Pleads Guilty to Insider Trading in FDA Drug Case - NewsBreak
ACADIA Pharmaceuticals (NASDAQ:ACAD) Upgraded at StockNews.com - Defense World
Ex-San Diego biotech company CEO admits to illegally selling $1.3M worth of shares - FOX 5 San Diego
Former Pharmaceutical Executive Pleads Guilty After $1.3M Gain from Insider Trading - Times of San Diego
Balanced Outlook for ACADIA Pharmaceuticals Amid Uncertain Long-term Growth Prospects - TipRanks
ACADIA Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
ACADIA Pharmaceuticals Inc. to Host Earnings Call - ACCESS Newswire
Why ACADIA Pharmaceuticals Stock Took a Hit - TipRanks
Ex-San Diego biotech company VP admits to illegally selling $1.3M worth of shares - fox5sandiego.com
ACADIA Pharmaceuticals Director Makes Significant Stock Sale - TipRanks
Insider Sell: Elizabeth Garofalo Sells 4,919 Shares of ACADIA Ph - GuruFocus.com
Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock By Investing.com - Investing.com South Africa
Acadia Pharmaceuticals director Elizabeth Garofalo sells $89,673 in stock - Investing.com India
Acadia Pharmaceuticals (ACAD) Q4 Earnings Lag Estimates (Revised) - MSN
How Biopharma Leaders Are Leveling Up Sales Strategies For 2025 - FiercePharma
Acadia reports DAYBUE safe for young Rett syndrome patients - Investing.com
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):